What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here?

Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug Administration-approved drugs could provide significant revenue growth in the coming years. Sales of its bad cholesterol-lowering drug Praluent are starting to pick up, and the eczema drug Dupixent and rheumatoid arthritis drug Kevzara have recently launched.In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss the opportunities -- and the risks -- associated with Regeneron's newest products.A full transcript follows the video.Continue reading

BING NEWS:
  • Regeneron to collaborate on gene editing therapies with Doudna-founded Mammoth
    Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
    04/25/2024 - 8:10 am | View Link
  • Regeneron, Mammoth Launch In Vivo CRISPR Gene Editing Collaboration
    Regeneron Pharmaceuticals will use Mammoth Biosciences’ CRISPR-based ultracompact gene editing platform to develop in vivo therapies for tissues and cell types beyond the liver.
    04/25/2024 - 4:00 am | View Link
  • Jennifer Doudna co-founded Peninsula biotech lands CRISPR gene-editing pact with Regeneron
    The big deal between Regeneron and a Peninsula biotech co-founded by Jennifer Doudna is also a small deal. And that’s a huge deal.
    04/25/2024 - 2:27 am | View Link
  • Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
    The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Danaher Corp. (DHR), Regeneron ...
    04/24/2024 - 8:51 am | View Link
  • Can Growing Adoption Of Arcalyst Drive KNSA Stock Up?
    Kiniksa Pharmaceuticals Ltd.'s (KNSA) flagship product Arcalyst has garnered widespread acclaim and acceptance since its launch in ...
    04/24/2024 - 3:28 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News